Friday, September 18, 2026

Preventive Cardiology · Imaging · Access

Beyond the Tertiary Center: Bringing Coronary Atherosclerosis Detection to Rural Patients

Community CT scanners, opportunistic calcium reads, the PREVENT equations, and remote cardiology consultation can move detection upstream for patients who live far from a heart center.

Cardiology blog · September 18, 2026 · Audience: cardiologists and primary care physicians · Reading time ≈ 9 min

The burden sits where the specialists are not

The 2026 AHA Heart Disease and Stroke Statistics update counts 915,973 US cardiovascular deaths in 2023, more than cancer and accidents combined.

The same report estimates that about 47% of US adults have hypertension, roughly 29.5 million have diagnosed diabetes, and close to 90% have some degree of cardiovascular-kidney-metabolic (CKM) syndrome.

A JACC county-level workforce analysis found no practicing cardiologist in 46.3% of US counties, a gap that covers 86.2% of rural counties and about 22 million residents.

Patients in those counties faced an average 87.1-mile round trip to the nearest cardiologist, compared with 16.3 miles elsewhere, and the mismatch between disease burden and specialist supply was largest in the South.

A separate JACC analysis of 2010–2022 mortality showed age-adjusted cardiovascular death rates rising in rural counties while falling in urban ones, with the widening driven mostly by adults aged 25 to 64.

Age-adjusted cardiovascular mortality, rural versus urban counties, 2010 and 2022 Rural counties rose from 431.6 to 435.0 deaths per 100,000; urban counties fell from 369.3 to 345.5 per 100,000. Age-adjusted CV deaths per 100,000 Rural Urban faded bar = 2010 · solid bar = 2022 0 100 200 300 400 500 Rural · 2010 431.6 Rural · 2022 435.0 Urban · 2010 369.3 Urban · 2022 345.5 2022 rural-vs-urban relative risk 1.53; 1.25 after adjustment for poverty, education, and uninsurance.
Visual 1. Rural cardiovascular mortality edged up between 2010 and 2022 while urban mortality declined; bar lengths are drawn to scale from the reported rates. Original graphic based on the JACC analysis reported by TCTMD.
Table 1. The rural access gap in numbers
MeasureRural / underservedComparison
Counties without a practicing cardiologist86.2% of rural counties46.3% of all US counties
Round-trip distance to nearest cardiologist87.1 miles16.3 miles
Age-adjusted CV mortality, 2022 (per 100,000)435.0345.5 (urban)
Safety-net hospitals offering CCTA22% (rural)57% (urban)
Safety-net hospitals offering CCTA, by size7.7% (6–49 beds)88.9% (400+ beds)

Why the default pathway misses the asymptomatic rural patient

Functional stress testing remains the reflexive first test in many practices, yet it is ordered only after symptoms or suspicion appear and is built to detect flow-limiting stenosis rather than early plaque.

For a patient who lives an hour or more from the nearest stress lab, the fasting, medication holds, multi-hour imaging protocols, and occasional driving restrictions translate into a lost workday and a ride that must be arranged.

The coronary artery calcium (CAC) score is the closest thing to a direct screen for subclinical atherosclerosis, but Original Medicare does not cover it, so most patients pay roughly $100 to $150 out of pocket when they can find a scanner.

Coronary CT itself is thin on the ground outside large centers, as a survey of 391 safety-net hospitals found CCTA available at only 22% of rural facilities versus 57% of urban ones.

What rural adults most often receive instead is a lipid panel and a blood pressure check, which identify risk factors but cannot show whether plaque is already present.

Anatomy-first evidence is now long-term

The SCOT-HEART 10-year follow-up showed that adding CCTA to standard care in stable chest pain lowered coronary death or nonfatal MI from 8.2% to 6.6% (HR 0.79; 95% CI 0.63–0.99).

Nonfatal MI alone fell from 6.0% to 4.3% (HR 0.72), and the benefit tracked with greater use of preventive therapy, mainly statins, in the CT arm (56% vs 49%).

The mechanism matters for rural care, because the dividend of CT came from seeing non-obstructive plaque and treating it, which is work a primary care clinician can carry out locally once the anatomy is known.

The 2021 AHA/ACC chest pain guideline already gives CCTA a Class 1 role in intermediate-risk stable and acute chest pain, so the evidence base for an anatomy-first strategy is not the barrier.

Four tools that travel

1. PREVENT at the primary care visit

The 2026 ACC/AHA dyslipidemia guideline, released March 13, 2026, replaces the pooled cohort equations with the AHA PREVENT equations for adults aged 30 to 79 without known ASCVD.

PREVENT runs on data every rural clinic already collects, including lipids, systolic blood pressure, eGFR, diabetes status, smoking, and treatment history, and it returns both 10-year and 30-year estimates.

The guideline sorts 10-year PREVENT-ASCVD risk into low (<3%), borderline (3% to <5%), intermediate (5% to <10%), and high (≥10%) tiers, with LDL-C goals of <100 mg/dL for borderline or intermediate risk and <70 mg/dL for high risk.

It also recommends a one-time lipoprotein(a) measurement in adulthood, a cheap blood test that flags inherited risk without any imaging.

2. Selective and opportunistic calcium scoring

The guideline's "calculate, personalize, reclassify" model supports CAC in men aged 40 or older and women aged 45 or older at borderline or intermediate risk when the statin decision is uncertain, and any detectable calcium supports an LDL-C goal below 100 mg/dL.

An AHA scientific statement on opportunistic CAC notes that about 19 million noncardiac chest CT scans are performed in the US each year, against roughly 1 million dedicated calcium scans.

Many rural hospitals already run low-dose CT lung cancer screening and trauma or pulmonary CT, so a structured calcium read on scans that already exist costs nothing in travel or radiation.

In the randomized NOTIFY-1 project, simply notifying clinicians and patients about AI-detected incidental calcium raised 6-month statin prescribing to 51.2%, versus 6.9% with usual care.

3. Community-based CCTA with remote reading

A CCTA-capable scanner needs far less capital and staffing than a catheterization laboratory, and the acquisition can be performed by a trained CT technologist while an experienced cardiac CT reader interprets the study from anywhere.

Hospital outpatient payment for CCTA roughly doubled when CMS moved codes 75572–75574 into APC 5572, lifting the technical payment from about $175 in 2024 to $357 in 2025.

That placement continues in 2026 only on a provisional basis, so hospitals are being urged to update their CCTA charges so that cost data support keeping the higher rate.

AI-enabled plaque analysis gained a Category I CPT code (75577) on January 1, 2026, and Heartflow Plaque Analysis now reports coverage from Medicare and four large national commercial payers.

4. Telehealth and eConsults as the specialist bridge

The Consolidated Appropriations Act of 2026 extended Medicare telehealth flexibilities through December 31, 2027, including care delivered to patients at home regardless of rural status or originating site.

In a cluster-randomized cardiology eConsult trial at a community health center, median time to specialist input fell from 24 days to 5 days, and 69% of eConsults were resolved without a face-to-face cardiology visit.

The same trial recorded fewer cardiac emergency department visits in the eConsult arm, which suggests that faster input need not come at the expense of safety.

Table 2. The rural detection toolkit at a glance
ToolWhat it detectsLocal infrastructureWho acts on it2026 coverage / payment note
PREVENT equations10- and 30-year risk (no disease detection)Routine labs and vitalsPrimary carePart of a routine visit
Lipoprotein(a)Inherited risk enhancerStandard labPrimary careOnce per lifetime per guideline
Dedicated CAC scanCalcified plaque burdenAny modern CTPrimary care, with cardiology inputNot covered by Original Medicare; cash price often $100–150
Opportunistic CACCalcium on existing chest CTExisting scans plus reporting protocolRadiology → primary careNo new scan; depends on structured reporting
CCTAStenosis, total plaque, high-risk features≥64-slice CT, trained technologistRemote cardiac CT reader → primary care or cardiologyHospital outpatient APC 5572 (provisional in 2026)
AI plaque analysisQuantified plaque volume and compositionCloud-based software on CCTA dataCardiologyCPT 75577 (from January 2026); Heartflow HTFL, Cleerly (no ticker, private)
eConsult / video visitSpecialist triage of resultsEHR messaging or video linkCardiology ↔ primary careMedicare telehealth flexibilities through December 2027

A hub-and-spoke pathway for primary prevention

Stitched together, these tools let the rural primary care clinic serve as the front door while the cardiologist acts as the remote interpreter and the tertiary center handles only the patients who need a procedure.

Rural detection pathway Primary care calculates PREVENT risk; low risk gets lifestyle care, borderline to intermediate risk gets selective or opportunistic calcium scoring, high risk starts a statin; symptoms at any stage lead to community CCTA with remote reading, followed by local prevention, eConsult with functional testing, or transfer to the hub. Rural primary care visit PREVENT-ASCVD from lipids, BP, eGFR, diabetes, smoking · one-time Lp(a) Low (<3%) Lifestyle care; periodic reassessment 3% to <10% Selective CAC, or read calcium on an existing chest CT High (≥10%) Start statin; LDL-C goal <70 mg/dL CAC = 0 Statin often deferred; weigh risk enhancers CAC > 0 Statin; LDL-C <100 mg/dL, lower goals as CAC rises symptoms at any stage Community CCTA first-line Acquired by a local CT technologist · read remotely by a cardiac CT reader ± AI plaque analysis or CT-FFR · report routed to primary care and cardiology CAD-RADS 0–2 Intensify prevention locally; telehealth follow-up CAD-RADS 3–4A Cardiology eConsult; CT-FFR or functional test; GDMT CAD-RADS 4B–5 Left main or 3-vessel disease, occlusion: refer to hub for angiography
Visual 2. A hub-and-spoke detection pathway combining 2026 ACC/AHA risk tiers, selective or opportunistic CAC, and community CCTA with remote reading; thresholds follow the 2026 dyslipidemia guideline and CAD-RADS 2.0, and local protocols should govern individual decisions. Original graphic.

Paying for the spokes

The CMS Rural Health Transformation Program is distributing $50 billion over federal fiscal years 2026 to 2030, with every state receiving a $100 million baseline plus workload-based funding in the first year.

Its permitted uses explicitly include equipment, digital tools, telehealth systems, workforce training, and regional care networks, which map directly onto scanners, remote reading, and eConsult platforms.

Because states control how the money is distributed, cardiology groups that want to seed a community CT or eConsult program need to engage their state rural health office early.

Therapy that follows detection

The downstream intervention after a positive calcium or CCTA finding is usually an inexpensive generic statin, which keeps the cost of acting on a rural screening result low for patients.

Table 3. First-line statins used after a positive CAC or CCTA result
GenericBrand · manufacturerRole in this pathwayUS retail pricing*
AtorvastatinLipitor · Viatris VTRSModerate- or high-intensity therapy toward the guideline LDL-C goalGeneric from about $7–12 with GoodRx coupons
RosuvastatinCrestor · AstraZeneca AZNHigh-intensity option when greater LDL-C lowering is neededGeneric from about $12 with GoodRx coupons

*Pricing is time-sensitive (checked September 2026) and varies by pharmacy, dose, quantity, plan, and region; confirm on GoodRx or the manufacturer site.

Case scenario (fictional)

A 61-year-old former smoker who farms about 80 miles from the nearest cardiology office has a routine visit at his county clinic, with a total cholesterol of 212 mg/dL, HDL-C of 41 mg/dL, systolic blood pressure of 142 mmHg on one agent, and normal kidney function.

His 10-year PREVENT-ASCVD estimate falls in the intermediate tier, and a lung cancer screening CT performed at the local hospital a year earlier had mentioned "moderate coronary artery calcification" without any follow-up.

The nurse practitioner sends a cardiology eConsult, and the reviewing cardiologist answers within two days that the documented calcium settles the statin question without a dedicated calcium scan.

Atorvastatin 40 mg is started with an LDL-C goal below 100 mg/dL, and his blood pressure regimen is intensified.

Seven months later he reports new exertional chest tightness, and CCTA at the regional hospital 25 minutes away, read remotely, shows 25–49% proximal LAD stenosis with moderate plaque burden (CAD-RADS 2/P2) and no high-risk features.

Management stays local, with statin intensification, antianginal therapy, and a telehealth cardiology follow-up, and no trip to the tertiary center is needed.

Bottom line

Rural cardiovascular mortality is moving the wrong way while nearly nine in ten rural counties have no cardiologist, so detection has to happen where patients already receive care.

PREVENT and a one-time Lp(a) cost nothing beyond a routine visit, opportunistic calcium reads use scans that already exist, and community CCTA with remote interpretation brings the SCOT-HEART prevention dividend to towns without a heart center.

Telehealth flexibilities through 2027, improved CCTA payment, a new plaque-analysis code, and Rural Health Transformation funds make 2026 a practical year to build the spokes, with the cardiologist serving as interpreter and escalation point rather than gatekeeper.

References

  1. ACC/AHA issue updated guideline for managing lipids, cholesterol. American College of Cardiology, March 13, 2026.
  2. What the latest heart disease and stroke numbers mean for your health. American Heart Association News, January 21, 2026.
  3. No practicing cardiologist in nearly half of US counties, despite higher CV, mortality risk. American College of Cardiology, July 2024.
  4. Rural counties bore brunt of worsening CV mortality during pandemic. TCTMD.
  5. Ten-year outcomes of the SCOT-HEART study. Clinician.com (summary of the Lancet report).
  6. Opportunistic detection of coronary artery calcium on non-cardiac chest CT: top things to know. American Heart Association Professional Heart Daily.

Further viewing

Physician education disclaimer: This article is an educational synthesis for healthcare professionals and does not replace the source guidelines, local protocols, payer policies, or individual clinical judgment; the case scenario is fictional.

Financial disclaimer: Company tickers, payment figures, and drug prices are provided for identification and context only, are time-sensitive (checked September 2026), and are not investment or purchasing advice.

Cardiac CT · Atherosclerosis Imaging · September 2026

Who Is Behind AI Coronary Plaque Analysis?

A quick guide to the companies turning CCTA into quantitative plaque data.

AI-enabled quantitative coronary plaque analysis (AI-QCT) measures total plaque volume, non-calcified and low-attenuation plaque from a standard CCTA. The main US players are HeartFlow Plaque Analysis, Cleerly, Elucid PlaqueIQ (which adds histology-validated plaque morphology), and Caristo CaRi-Plaque. Newer FDA-cleared tools include Artrya Salix, Circle cvi42|Plaque and Keya Medical.

The field grew once Medicare set payment under Category I CPT 75577 (effective 2026). Caristo also goes beyond plaque. Its CaRi-Heart received FDA De Novo authorization in July 2026 for measuring coronary inflammation with the perivascular fat attenuation index (FAI), which is supported by ORFAN. Several vendors are also linking plaque results with CT-FFR into one report.

Key message: AI-QCT turns a CCTA into a measure of atherosclerotic burden, not just a stenosis grade. Plaque burden predicted MI better than stenosis in SCOT-HEART. However, outcome trials showing that plaque-guided therapy improves outcomes are still pending. Vendor numbers also cannot be used interchangeably, so serial scans should be analyzed with the same platform.

What it pays: in 2026, Medicare pays about $951 in the hospital outpatient setting (APC 1511) and about $1,012 in physician offices and imaging centers for CPT 75577. This is paid on top of the CCTA itself. Commercial coverage is growing: Aetna, Cigna, Humana and UnitedHealthcare have policies, but coverage typically requires stable chest pain and an intermediate CCTA result (CAD-RADS 1–3). For comparison, one well-known CT program charges self-pay patients around $850 for the analysis alone.

What vendors charge and what sites keep: none of the vendors publish their per-case fees. These are negotiated in contracts, so there is no verified public figure for hospital or practice profit. The margin is the Medicare payment minus the vendor fee, staff time and overhead. It depends heavily on contract terms, payer mix and denial rates. On-premise software (for example Circle cvi42) is marketed as keeping more of the payment in-house, while cloud services charge per case.

CPT 75577 (2026) Approx. payment
Medicare, hospital outpatient~$951
Medicare, office / imaging center~$1,012 (national average)
Commercial insuranceNegotiated; varies by plan and criteria
Self-pay (analysis only)~$850 at one reported site; varies
Vendor fee / site marginNot publicly disclosed
Company Product Distinctive feature
HeartFlowPlaque AnalysisBuilt into the FFRct workflow
CleerlyCleerly Plaque / ISCHEMIAPlaque staging plus AI ischemia estimate
ElucidPlaqueIQHistology-validated tissue characterization
CaristoCaRi-Plaque / CaRi-HeartPlaque plus perivascular inflammation (FAI)
Artrya · Circle CVI · KeyaSalix · cvi42|Plaque · DeepVesselNewer FDA-cleared options
References & Further Reading
  1. SCOT-HEART: Low-Attenuation Plaque and MI (Circulation 2020)
  2. ORFAN: Coronary Inflammation and Cardiac Risk (Lancet 2024)
  3. Scientific Statements on AI Plaque Evaluation
  4. CPT 75577 and AI Plaque Reimbursement
  5. HeartFlow Next-Generation Plaque Analysis Clearance
  6. Elucid PlaqueIQ Reimbursement
  7. Caristo CaRi-Heart FDA De Novo (2026)
  8. Artrya Salix FDA Clearance
  9. Circle cvi42|Plaque FDA Clearance
  10. Medicare 2026 Payment for CPT 75577
  11. AI Plaque Reimbursement and Commercial Coverage (Circle CVI)
  12. Cleerly Coverage Criteria
  13. STAT: Medicare to Cover $1,000 AI Heart Scans

Status as of September 18, 2026, based on company and trade-press reports. Payment figures are national Medicare estimates before geographic adjustment and are not billing advice. For educational purposes only; not an endorsement of any product.

Wednesday, September 16, 2026

Cardiac CT · Consensus Statement Review

A new clinical consensus statement moves cardiac CT from a specialist tool to a front-line test, and it sets clear expectations for how referrals, acquisitions, and reports should look.

Source: European Heart Journal, advance article, August 2026 · Audience: practicing cardiac CT readers · Reading time ≈ 12 min

Graphical Abstract — the scope of cardiac CT across clinical scenarios
The statement's visual summary maps cardiac CT onto ischaemic heart disease, valve disease, cardiomyopathies, masses, large vessels, and adult congenital heart disease.
Source: Eur Heart J 2026; ehag389, Graphical Abstract. © The European Society of Cardiology 2026 — linked, not reproduced.

1. Why this statement matters

The EACVI/ESC clinical consensus statement is written for the general cardiologist who orders the scan, which makes it a practical reference for the reader who interprets it.

Key points

  • It is a joint document of the European Association of Cardiovascular Imaging (EACVI) and the ESC Council for Cardiology Practice, published as an official statement in the European Heart Journal.
  • Its stated aim is to raise the confidence of non-imaging cardiologists in requesting cardiac computed tomography (CCT).
  • Scope extends well past coronary disease to valvular disease, cardiomyopathies, cardiac masses, large-vessel disease, and adult congenital heart disease.
  • Each clinical section is built the same way: indication, technical assessment, prognostic value, what the referral should contain, and how to read the report.
  • For readers, the "what the referral should contain" sections are effectively a template for protocol selection and report tailoring.

2. Scanner technology and acquisition

The statement treats 64-slice CT as the minimum platform and frames newer hardware as a way to widen the pool of scannable patients.

Key points

  • 64-slice systems are the floor, with temporal resolution as their main constraint.
  • Dual-source CT (DSCT) and wide-detector scanners (>256 slices) improve temporal resolution and coverage per rotation.
  • Photon-counting detector CT (PCD-CT) pairs high temporal resolution with spatial resolution down to about 0.2 mm, which matters most for calcium blooming and stent lumens.
  • Core requirements are unchanged: a 5–10 s breath-hold, ECG synchronisation, an unenhanced scan for calcium scoring, and iodinated contrast for CCTA.
Figure 1 — Fundamentals of the main CCT scanner types
A side-by-side schematic of conventional multidetector, dual-source, wide-coverage, and photon-counting platforms.
Source: Eur Heart J 2026; ehag389, Figure 1. © ESC 2026 — linked, not reproduced.

3. Patient preparation, heart-rate control, and dose

Image quality is decided before the scan starts, so the statement spells out contraindications, limiting factors, and a premedication menu (its Table 1).

Key points

  • Contraindications include prior moderate or severe iodinated contrast reactions, asthma or atopy requiring treatment, pregnancy, renal impairment, and clinical instability.
  • Patient factors that erode accuracy are high heart rate (target ≤60 bpm), heart-rate variability, obesity, and breathing artefact.
  • Dose follows ALARA, with a typical mean effective dose near 3 mSv and <1 mSv achievable on current platforms.
  • Dose-saving levers are prospective ECG triggering, high-pitch spiral acquisition, iterative and deep-learning reconstruction, better detector efficiency, and tube-current modulation.
Table 1. Heart-rate and vasodilator premedication (per the statement) with product details
Agent (generic)Brand · manufacturerStatement regimenReader notesUS pricing*
Metoprolol tartrate (oral)Lopressor; widely generic (multiple manufacturers)100 mg PO, 1 h before scanCheck BP, bronchospasm history, and AV conduction firstLow-cost generic; pricing varies
Metoprolol (IV)Generic injection5–20 mg IV, 5–10 min before scanTitrate in the scanner to the target rateInstitutional supply
IvabradineCorlanor · Amgen AMGN; Procoralan (EU) · Servier (no ticker, private)5–7.5 mg BID for 2–3 daysUseful when beta-blockers are contraindicated; requires sinus rhythmGeneric from roughly $45–56 via GoodRx
Nitroglycerin (sublingual)Nitrostat · Viatris VTRS800 µg, 5 min before scanHold with PDE-5 inhibitor use, severe AS, or hypotensionGeneric from roughly $9 via GoodRx

*Pricing is time-sensitive (checked September 2026) and varies by pharmacy, plan, and region; confirm on GoodRx or the manufacturer site.

4. Post-processing toolkit

The statement lists the standard reconstructions and makes clear that axial source images remain the reference.

Key points

  • Trans-axial images are the primary 2D dataset and the place to confirm any finding.
  • Multiplanar reformation (MPR) displays the 3D volume in any plane.
  • Curved MPR (cMPR) follows the vessel centreline for longitudinal and true cross-sectional views, and depends on an accurate centreline.
  • Maximum intensity projection (MIP) highlights high-attenuation structures such as contrast and calcium.
  • Volume rendering (VR) shows spatial relationships and is best for communication, not stenosis grading.
Figure 2 — Main image-analysis methods
Examples of axial, MPR, curved MPR, MIP, and volume-rendered displays from one coronary dataset.
Source: Eur Heart J 2026; ehag389, Figure 2. © ESC 2026 — linked, not reproduced.

5. What CCT can evaluate

Coronary assessment is the core use, while chambers, valves, and great vessels are covered when other modalities fall short or when anatomy drives decisions.

Key points — coronaries

  • Detects and classifies anomalous coronary origins.
  • Grades stenosis presence, location, extent, and severity with a standard scale (statement Table 2: 0%, <25%, 25–49%, 50–69%, 70–99%, 100%).
  • Classifies plaque as non-calcified, calcified, or partially calcified.
  • Flags adverse plaque features: low-attenuation plaque, positive remodelling, spotty calcification, and the napkin-ring sign.
  • Quantifies plaque burden with the AHA 16-segment model or SCCT segmentation.

Key points — chambers, valves, vessels

  • CCT is not a first-line test for chamber size or function unless echocardiography or CMR is limited or contraindicated.
  • Retrospective ECG gating gives LV and RV volumes, mass, and function that agree well with CMR, at a dose cost.
  • Valve anatomy, leaflet thickening, and leaflet calcification are clearly shown.
  • ECG-triggered scans give precise aortic measurements and detect atheroma, thrombus, intramural haematoma, penetrating ulcer, and dissection flaps.
  • The left atrium, pulmonary veins, and pulmonary arteries to the subsegmental level are well shown.

6. Coronary calcium score and CAC-DRS

The statement places the coronary artery calcium score (CACS) firmly in asymptomatic risk stratification and warns against reading it as a stenosis test.

Key points — technique

  • ECG-gated, non-contrast acquisition with a short breath-hold and dose <1.0 mSv.
  • A calcified lesion is any area ≥1 mm² at ≥130 HU.
  • Lesion score = area (mm²) × density weight, where the weight is set by peak attenuation (see chart).
Agatston density weighting by peak attenuation Step chart: 130 to 199 HU weight 1, 200 to 299 HU weight 2, 300 to 399 HU weight 3, 400 HU or more weight 4. 01234 Density weight ×1×2×3×4 130200300400HU Peak lesion attenuation (HU) · threshold 130 HU, minimum area 1 mm²
Visual 1. Agatston density weighting; each lesion's area is multiplied by its weight and summed across the coronary tree. Original graphic based on values reported in the statement.

Key points — prognosis

  • CACS predicts cardiovascular events regardless of age, sex, or ethnicity, and adds to ESC SCORE and Framingham risk estimates.
  • In the Heinz Nixdorf Recall (HNR) study, adding CACS to Framingham gave a net reclassification improvement of about 22%, moving roughly a quarter of intermediate-risk subjects down and about a fifth up.
  • CACS = 0 carries much lower event rates and lets statin therapy be deferred in suitable patients.
  • CACS >100 or ≥75th percentile for age and sex supports statin initiation in line with ACC/AHA practice.
  • CACS = 0 does not exclude obstructive non-calcified disease, particularly in younger or symptomatic patients.
Table 2. What a CAC report should contain (CAC-DRS framework)
ElementContentReader tip
Total scoreCategories 0 · 1–99 · 100–299 · ≥300Map to CAC-DRS 0–3
PercentileAge-, sex- (and ideally ethnicity-) matched comparisonName the reference database used
DistributionNumber of vessels involved (N0–N4)Include left main involvement explicitly
Coding"Category/N" format, e.g. CAC-DRS 2/N3Pair with a plain-language risk sentence
Figure 3 — How the calcium score is calculated
A worked example of lesion outlining, area measurement, and density weighting on a non-contrast scan.
Source: Eur Heart J 2026; ehag389, Figure 3. © ESC 2026 — linked, not reproduced.
Figure 4 — Examples across CACS categories
Representative scans spanning zero, mild, moderate, and severe calcium burden.
Source: Eur Heart J 2026; ehag389, Figure 4. © ESC 2026 — linked, not reproduced.

7. CCTA in acute chest pain

For low-to-intermediate likelihood ACS, the statement endorses CCTA as a fast route to safe discharge or to targeted invasive care.

Key points — indications and protocol

  • Candidates are low-to-intermediate likelihood patients, including those managed with the ESC 0h/1h and 0h/2h hs-troponin algorithms.
  • A triple rule-out protocol covers pulmonary embolism and acute aortic syndrome in one acquisition, but it uses a different protocol and more contrast.
  • The referral must state rule-out ACS versus triple rule-out, plus risk profile, symptoms, ECG, troponin, and tolerance of beta-blockers and nitrates.
  • Readers should expect notes on likely quality limits: heavy calcium, irregular rhythm, and obesity.

Key points — evidence

  • CT-STAT (16 EDs) cut time to diagnosis by 54% (2.9 h vs 6.3 h) and costs by 38% versus rest-stress MPI.
  • ACRIN-PA and ROMICAT-II showed no excess MACE about one month after a CT-first strategy.
  • In ROMICAT, no CAD meant no MACE over 2 years, while non-obstructive disease carried about 4% two-year MACE risk and warrants prevention.
  • High-risk plaque was more common in ACS in ROMICAT-II and stayed an independent predictor after adjusting for ≥50% stenosis.
  • RAPID-CTCA found faster diagnostic clarity with early CCTA but no improvement in 1-year clinical outcomes, so patient selection matters.
  • Non-obstructive to mild CAD supports early discharge; more than moderate disease needs further risk stratification.
Figure 5 — CCT in a patient with acute chest pain
An illustrative emergency-department case showing how CCTA findings steer discharge or invasive management.
Source: Eur Heart J 2026; ehag389, Figure 5. © ESC 2026 — linked, not reproduced.

8. CCTA in chronic coronary syndrome

The statement frames CCTA as a safe first-line anatomical test in chronic coronary syndrome (CCS), in line with the 2024 ESC CCS Guidelines, and points to outcome gains that come mainly from better prevention.

Key points — diagnostic performance

  • In PACIFIC, per-patient accuracy was 85% for PET, 77% for SPECT, 74% for CCTA, and 84% for hybrid PET-CCTA.
  • CCTA performs especially well in women, finding both obstructive and non-obstructive atherosclerosis with better prognostic value than stress testing.
  • CCTA alone cannot diagnose INOCA, which needs a functional test on top of anatomy.

Key points — outcome trials

  • In the CONFIRM registry, ≥50% and ≥70% stenoses and proximal LAD or left main disease predicted death, and no CAD gave a 99.7% negative predictive value for near-term mortality.
  • PROMISE (10,003 patients) found no outcome difference versus functional testing, but fewer non-obstructive invasive angiograms with CCTA (3.4% vs 4.3%).
  • SCOT-HEART changed the diagnosis in 27% of patients and cut CHD death or MI at 5 years (2.3% vs 3.9%), driven by more preventive therapy.
  • DISCHARGE (3,561 patients) showed CCTA non-inferior to invasive angiography for MACE at 3.5 years (2.1% vs 3.0%), with fewer major procedural complications (0.5% vs 1.9%).
  • CONSERVE showed that CCTA-guided selective catheterisation reduced unneeded invasive procedures without harming outcomes.
  • In ICONIC, drawn from about 25,000 patients, roughly two-thirds of those who later had ACS showed only non-obstructive disease at baseline.
Key CCTA outcome trials Paired bars: SCOT-HEART CHD death or MI 2.3 percent CCTA vs 3.9 percent standard care; DISCHARGE MACE 2.1 vs 3.0 percent; DISCHARGE major complications 0.5 vs 1.9 percent; PROMISE non-obstructive invasive angiography 3.4 vs 4.3 percent. 0%1%2%3%4%5% CCTA strategy Comparator SCOT-HEART CHD death/MI, 5 y 2.3% 3.9% DISCHARGE MACE, 3.5 y (vs ICA) 2.1% 3.0% DISCHARGE Major complications 0.5% 1.9% PROMISE Non-obstructive ICA 3.4% 4.3% Comparators: SCOT-HEART standard care · DISCHARGE invasive angiography · PROMISE functional testing
Visual 2. Event and procedure rates in the landmark CCTA trials cited by the statement; bar lengths are drawn to scale from the reported percentages. Original graphic.

9. Plaque: high-risk features and statins

The statement treats plaque phenotype as prognostic information worth reporting, while cautioning that a vulnerable-looking plaque is not destiny.

Key points

  • In a PROMISE substudy of more than 4,000 patients, high-risk plaque (HRP) carried about 2.7-fold higher risk of death, MI, or unstable angina, rising to an adjusted HR of 4.31 in non-obstructive disease.
  • In a SCOT-HEART substudy, CHD death or non-fatal MI was 4.1% with HRP versus 1.4% without (HR 3.01).
  • In CONFIRM, about 40% of patients with HRP never had an ACS, since an additional trigger is needed for plaque to cause an event.
  • In a serial-CCTA registry of 1,255 patients followed for 3.8 years, statin therapy slowed plaque progression, increased calcific conversion, and reduced new HRP features.
  • Practical implication: report HRP on every study where it is present, because it shifts preventive intensity even when stenosis is mild.

10. Reporting with CAD-RADS 2.0

The statement adopts CAD-RADS 2.0 as the reporting language, pairing stenosis grade with plaque burden and modifiers.

CAD-RADS 2.0 stenosis categories and suggested management Seven rows from CAD-RADS 0 to 5 with stenosis ranges and management: 0 and 1 to 2 prevention, 3 functional testing, 4A invasive angiography or functional testing, 4B and 5 invasive angiography. CATEGORYMAX STENOSISSUGGESTED NEXT STEP CAD-RADS 00% · no plaqueReassure; usual risk-factor care CAD-RADS 11–24%Preventive therapy CAD-RADS 225–49%Preventive therapy CAD-RADS 350–69%Functional test (or CT-FFR) CAD-RADS 4A70–99%, 1–2 vesselsElective ICA or functional test CAD-RADS 4BLM ≥50% or 3-vessel ≥70%Invasive angiography CAD-RADS 5100% occlusionInvasive angiography
Visual 3. CAD-RADS 2.0 stenosis ladder with the management steps summarised in the statement for stable patients; always integrate symptoms and clinical context. Original graphic.
Table 3. CAD-RADS 2.0 plaque burden (P) and modifiers
DescriptorDefinitionPractical use
P1 mildCACS 1–100 or SIS ≤2Consider preventive therapy
P2 moderateCACS 101–300 or SIS 3–4Preventive therapy
P3 severeCACS 301–999 or SIS 5–7Aggressive prevention
P4 extensiveCACS >1000 or SIS ≥8Aggressive prevention
NNon-diagnostic segment(s)State which segments and why
HRP≥2 high-risk plaque featuresFlag even with mild stenosis
I+ / I− / I±Ischaemia by CT-FFR or CT perfusionUse when a functional CT result is available
S · GStent · bypass graft presentComment on evaluability
EExceptions: anomaly, dissection, aneurysm, ectasia, fistulaDescribe the non-atherosclerotic finding

SIS = segment involvement score. Use either CACS or a plaque-burden method consistently. Example code: CAD-RADS 4A/P2/HRP.

Figure 6 — A CAD-RADS 4A/P3/HRP example
A worked case showing a severe stenosis with high-risk plaque features and severe overall plaque burden, coded in CAD-RADS 2.0.
Source: Eur Heart J 2026; ehag389, Figure 6. © ESC 2026 — linked, not reproduced.

11. Beyond the coronaries

The later sections of the statement cover functional CT and non-coronary indications, which is where many general cardiologists are least sure what to request.

Key points

  • CT perfusion and CT-derived FFR add a functional layer to intermediate stenoses, and the 2026 SCCT CT-FFR consensus standardises reading about 2 cm distal to the lesion.
  • Dedicated sections cover CCTA after PCI and CABG, valve disease, cardiomyopathies, cardiac masses, large-vessel disease, and adult congenital heart disease.
  • A closing section addresses extracardiac findings, which every reader must review and report.
  • Readers should use the full text for protocol detail in these areas, because indications and acquisition settings differ from standard CCTA.
Table 4. Non-coronary applications covered by the statement — common reader checklist
AreaTypical clinical questionAcquisition/reporting reminder (general practice)
Revascularised patientsGraft patency; in-stent restenosisStent size and platform limit evaluability; use sharp kernels and use S/G modifiers
Valve diseaseTAVI planning; prosthetic valve dysfunction; endocarditis complicationsSystolic annular measurements; leaflet thickening and motion need multiphase data
CardiomyopathiesTissue characterisation when CMR is not possibleLate iodine enhancement and ECV need a delayed acquisition
Cardiac massesThrombus vs tumour; LAA thrombus before ablation or cardioversionA delayed phase separates thrombus from slow flow
Large vesselsAneurysm size; acute aortic syndrome; PEECG-gated aortic root measurements; report inner-to-inner or outer-to-outer consistently
Adult CHDComplex anatomy, shunts, conduitsTailor contrast timing to the circulation being studied

Case vignette (fictional)

A 58-year-old woman with hypertension and dyslipidaemia reports exertional chest tightness for two months, with a normal resting ECG and normal echocardiogram.

Clinical likelihood is intermediate, and she has no contraindication to contrast.

Her resting heart rate is 74 bpm, so she receives oral metoprolol 100 mg an hour before the scan and sublingual nitroglycerin on the table, reaching 58 bpm.

The calcium score is 180 (P2), and CCTA shows a 70–79% stenosis in the proximal LAD made of partially calcified plaque with low attenuation and positive remodelling.

The report reads CAD-RADS 4A/P2/HRP, with a note on the proximal location and a recommendation for high-intensity statin therapy.

CT-FFR measured 2 cm distal to the lesion is 0.72, adding the I+ modifier.

She is referred for elective invasive angiography with the CT map in hand, and her preventive therapy is intensified regardless of the procedure's result.

Bottom line for the CCTA reader

The 2026 EACVI/ESC statement treats cardiac CT as a routine front-line test and expects readers to deliver more than a stenosis grade.

  • Demand structured referrals that state the clinical question, rule-out versus triple rule-out, and premedication tolerance.
  • Control heart rate to ≤60 bpm and keep dose ALARA, ideally below 3 mSv.
  • Report CACS with CAC-DRS, and CCTA with the full CAD-RADS 2.0 code including P, HRP, and modifiers.
  • Treat non-obstructive disease and HRP as prevention triggers, since that is where the outcome benefit in SCOT-HEART came from.
  • Add functional CT for CAD-RADS 3–4A where it is available, and always review extracardiac structures.

References

  1. Implementation of cardiac computed tomography in everyday practice: a clinical consensus statement of the EACVI of the ESC and the ESC Council for Cardiology Practice. European Heart Journal, 2026 (advance article; doi:10.1093/eurheartj/ehag389).
  2. CAD-RADS 2.0 – 2022 Coronary Artery Disease – Reporting and Data System: SCCT/ACC/ACR/NASCI expert consensus document. Radiology: Cardiothoracic Imaging, 2022.
  3. 2024 ESC Guidelines for the management of chronic coronary syndromes. European Society of Cardiology.
  4. Scottish Computed Tomography of the HEART (SCOT-HEART) — trial summary. American College of Cardiology.
  5. DISCHARGE hailed as a big step forward for CTA in stable chest pain. TCTMD, 2022.
  6. Fractional flow reserve in coronary CT angiography — 2026 expert consensus document. Society of Cardiovascular Computed Tomography.

Further viewing

About the figures: the statement is © The European Society of Cardiology 2026 with all rights reserved, so its figures are linked at the matching point in this review rather than reproduced; the three visuals shown here are original graphics drawn from the reported values. To embed the original figures, request reuse permission from Oxford University Press (journals.permissions@oup.com).

Physician education disclaimer: This article is a summary for healthcare professionals and does not replace the full consensus statement, applicable guidelines, local protocols, or individual clinical judgement; the case vignette is fictional.

Financial disclaimer: Manufacturer tickers and drug prices are given for identification only, are time-sensitive (checked September 2026), and are not investment or purchasing advice.

Tuesday, September 15, 2026

Cardiac CT · Physiology · September 2026

CT-FFR in 2026: How the Vendors Compare

CFD vs deep learning vs plaque-integrated physiology: one CPT code, several different engines.

HeartFlow FFRct is still the reference standard. It was first cleared in 2014, uses off-site computational fluid dynamics checked by analysts, and has the most outcomes data (NXT, PRECISE). Two FDA-cleared competitors take a different approach. Keya DeepVessel FFR (cleared in 2022) builds a 3D coronary tree and estimates FFR with deep learning in minutes. Cleerly ISCHEMIA (K231335) predicts lesion-level ischemia from AI plaque and stenosis features rather than a flow simulation.

All three bill under Category I CPT 75580. The AI plaque analysis code (CPT 75577, effective 2026) is now pushing companies to offer anatomy, plaque and physiology together. Two more CT-FFR products are coming. Elucid BioIntegrated FFR-CT adds plaque morphology to fluid dynamics and is under 510(k) review. Artrya Salix Coronary Flow is being prepared for FDA submission, with clearance targeted for the second half of 2026.

Key message: the vendors differ in evidence depth, turnaround time and how FFR is derived, not in how they are billed. Scanner-based on-site CT-FFR tools have randomized data outside the US (TARGET) but are not widely available in US practice. Whichever engine you use, CCTA image quality still limits the result, and values in the 0.75–0.80 gray zone still call for clinical judgment.

Vendor / product Method US status Evidence base
HeartFlow FFRct Off-site CFD, analyst-reviewed Cleared 2014; CPT 75580 Largest: NXT, PLATFORM, ADVANCE, PRECISE
Keya DeepVessel FFR Deep learning, semi-automated, minutes Cleared 2022; CPT 75580 US/EU pivotal study; large China experience
Cleerly ISCHEMIA AI plaque and stenosis model (no CFD) Cleared (K231335); CPT 75580 CREDENCE, PACIFIC validation
Elucid BioIntegrated FFR-CT CFD plus plaque morphology 510(k) pending Multicenter trials ongoing
Artrya Salix Coronary Flow AI-based, add-on to the Salix platform Pre-submission; clearance targeted 2H 2026 Validation completed (company-reported)